HALO: Financial results

Item 2.02 Results of Operations and Financial Condition. On November 5, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the third quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release dated November 5, 2026 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc (Registrant) Dated: November 5, 2026 By: /s/ Darren Snellgrove Darren Snellgrove Executive Vice President, Chief Financial Officer